Federal contractor · NORTH CHESTERFIELD, VA

INDIVIOR INC.

No contract obligations recorded for INDIVIOR INC. in FY2026. Since FY2020: $52.9M.

Obligations · FY2026: $0
New awards: 0
Sole-source: —
Single offer: —

UEI: VLCNBHCXCCJ9

Small business

Open in the contracts explorer Relationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

10.8KFY2020
32.4MFY2023
11.2MFY2024
9.3MFY2025

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for INDIVIOR INC. in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

INDIVIOR INC. received $0 in federal assistance in FY2026, on 0 actions (0 new awards), −100% vs FY2025.

Assistance · FY2026: $0
New awards: 0
Actions: 0
Since FY2022: $2.7M

Assistance by fiscal year

0FY2022
2.4MFY2023
287.2KFY2024
38.4KFY2025

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2022–FY2025.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 2 markets (agency × industry), FY2024–FY2026.

ACCORD BIOPHARMA, INC.$19.4M−35% in FY2026
RALEIGH, NC · 95% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Pharmaceutical and medicine manufacturing
SAGENT PHARMACEUTICALS, INC$17.4M−97% in FY2026
SCHAUMBURG, IL · 81% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Pharmaceutical and medicine manufacturing
HEYLTEX CORPORATION$17M−2.9% in FY2026
KATY, TX · 78% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Pharmaceutical and medicine manufacturing

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2024–FY2026.

Lobbying and PAC activity

Organizations in House lobbying disclosures and FEC records whose names an AI judgment matched to this company. Those records carry no identifier shared with contracts, so every match is by name.

Matched organizations

Indivior IncAI match · 100%

Lobbying · 2025: $980K; 13 reports
Lobbying · 2023–2026: $3.6M; $3.6M in its own reports

Lobbying by year

2023$1.1M
18 reports
2024$990K
19 reports
2025$980K
13 reports
2026$500K
6 reports

Top issues

Health issues43 reports
Medicare and Medicaid23 reports
Budget and appropriations13 reports
Pharmacy10 reports
Taxation and the Internal Revenue Code7 reports
Alcohol and drug abuse6 reports

Who was contacted

U.S. SENATE53 reports
U.S. HOUSE OF REPRESENTATIVES39 reports
Centers For Medicare and Medicaid Services (CMS)18 reports
Health & Human Services - Dept of (HHS)15 reports
White House Office15 reports
Substance Abuse & Mental Health Services Administration (SAMHSA)13 reports
Office of Natl Drug Control Policy (NDCP)11 reports
Justice - Dept of (DOJ)8 reports
Centers For Disease Control & Prevention (CDC)5 reports
Executive Office of the President (EOP)2 reports

Houses of Congress and federal agencies the reports list as contacted (a report names every one for all its issues).

Lobbying firms hired

Crossroads Strategies, LLC$530K
11 reports
PutalaStrategies$480K
8 reports
Williams and Jensen, PLLC$400K
7 reports
DLA Piper LLP (US)$360K
7 reports
Knight Capitol Consultants$280K
6 reports
JEFFREY J. KIMBELL & ASSOCIATES, INC.$20K
3 reports

Registrants who are individuals are counted, not named.

Lobbying amounts are the filers' own good-faith estimates on quarterly LD-2 reports (the law asks for amounts rounded to $10,000; under $5,000 need not be itemized), latest amendment only. When an organization files its own report, it replaces what outside firms report for it that quarter. Matches are by name. Lobbying and political giving are legal and public: they show engagement with government, not influence over any award. Correlation is not influence: these organizations' lobbying and their contracts are shown side by side, and nothing here implies either affected the other.

Source: Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives), data current to Oct 6, 2026, loaded Oct 6, 2026 · 2023–2026.

Source: Committees, candidates and committee contributions to candidates (Federal Election Commission), data current to Oct 6, 2026, loaded Oct 6, 2026 · 2026, 2024, 2022.

Matches: Analisa AI name judgments (entity-match@1), updated Sep 30, 2026.

Congress: members and bills

Through the organizations matched to this company: members of Congress whose campaigns received contributions from their PACs, and the bills their lobbying reports named. Shown beside the company's contracts as a comparison, not a cause.

Bills named in its lobbying reports

S. 3393 · SUPPORT for Patients and Communities Reauthorization Act15 reports
118th Congress · Reported by committee · 2023–2024
H.R. 4531 · Support for Patients and Communities Reauthorization Act13 reports
118th Congress · Passed one chamber · 2023–2024
H.R. 4007 · HEAL Act of 202310 reports
118th Congress · Introduced · 2023–2024
S. 2809 · HEAL Act of 202310 reports
118th Congress · Introduced · 2023–2024
H.R. 2400 · Reentry Act of 20238 reports
118th Congress · Introduced · 2023–2024
S. 1165 · Reentry Act of 20238 reports
118th Congress · Introduced · 2023–2024
S. 2624 · Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 20246 reports
118th Congress · Reported by committee · 2023–2024
H.R. 3074 · Due Process Continuity of Care Act5 reports
118th Congress · Introduced · 2023–2024
H.R. 4421 · Preparing for All Hazards and Pathogens Reauthorization Act5 reports
118th Congress · Introduced · 2023–2024
S. 2309 · Financial Services and General Government Appropriations Act, 20245 reports
118th Congress · Reported by committee · 2023–2024

28 of 56 reports (2023–2026) name at least one bill. Bills and resolutions the current reports name in their issue descriptions, by number of reports. A report names what it lobbied on, not which side it took.

Amounts, members and bills are as recorded, shown side by side. They say nothing about why a contribution was made, how a member voted or what a report sought. A bill number written in a report is read as the measure of the Congress its context points to (a law's number, the Congress written next to it, the title), else of the Congress then sitting.

Source: Committees, candidates and committee contributions to candidates (Federal Election Commission), data current to Oct 6, 2026, loaded Oct 6, 2026.

Source: Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives), data current to Oct 6, 2026, loaded Oct 6, 2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026.